| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_709b4a26ef028713f9b302509eb824d7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-095 |
| filingDate |
2013-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbf86feb6c6561f802f2bc356848c6b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0ea1e0cd65b2f452b03a736e9fe1b3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9f7a39f32877b312fa319c7ff98528c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30cf785ad118e166f20edd7a5c0f4c0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53c0629197eab4ad79aa8c4b94b8ced8 |
| publicationDate |
2015-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2013361164-A1 |
| titleOfInvention |
Methods and compositions relating to treatment of cancer |
| abstract |
Compositions and methods for treating cancer in a subject in need thereof are provided according to aspects of the present disclosure which include both cetuximab and ISC-4, as a combination formulation or as separate formulations. Methods of treating cancer in a subject in need thereof are provided according to aspects of the present disclosure wherein the subject has cancer characterized by wild-type KRAS wherein the methods include administering a combination of cetuximab and ISC-4 as a combination formulation or separately, and wherein administration of the combination of cetuximab and ISC-4 provides a synergistic anti-cancer effect, treating the cancer. |
| priorityDate |
2012-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |